Health groups ask India to rescind Gilead’s patents for COVID-19 drug remdesivir
Gilead’s three patents in India for remdesivir stem from 2009 when the drug was in development to treat Ebola
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Coronavirus vaccine possible in about a year, says EU agency
"For vaccines, since the development has to start from scratch ... we might look from an optimistic side in a year from now, so…
Merck registers an increase of 16.7 per cent in net sales
The COVID-19 crisis, which has meanwhile become a pandemic, only had a moderate impact in the first quarter of 2020, the company…
NovaLead Pharma to conduct Phase 3 trial for its repurposed anti COVID-19 drug
In a comparable viral assay study conducted by reputed laboratories in South Korea and United States, the drug, NLP21 has shown…
CDSCO examines export feasibility of hand sanitisers
Asks States /UTs to assess production, market availability of hand sanitisers
Indus Health Plus launches Hand Sanitiser
As organizations are planning to commence their operations gradually (as per the Govt. guidelines) there will be a surge in hand…
Exyte and Univercells Technologies to deploy vaccine production plants
The combined offer will enable users to rapidly deploy prefabricated GMP vaccine manufacturing facilities in response to the…
Lupin’s Vizag API Facility Receives EIR from US FDA
The inspection for the API facility was conducted by the US FDA between January 13, 2020 and January 17, 2020
Russia claims Favipiravir shows promise against coronavirus in early trials
Favipiravir is also undergoing trials in India by Glenmark Pharmaceuticals
Study reveals novel coronavirus may infect human intestines
Researchers were able to isolate SARS-CoV-2 from the stool specimen of a female patient diagnosed with COVID-19, which suggests…